Olorofim is a Small Molecule owned by F2G, and is involved in 15 clinical trials, of which 12 were completed, and 3 are ongoing.
Olorofim (F-901318) acts as DHODH inhibitor. DHODH is an enzyme involved in the de novo production of pyrimidines required for nucleic acid synthesis in fungus and catalyzes the oxidation of dihydroorotate to orotate. The drug candidate by inhibiting the enzyme prevents pyrimidine biosynthesis and blocks fungal growth thereby alleviates the condition.
The revenue for Olorofim is expected to reach a total of $413m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Olorofim NPV Report.
Olorofim is originated and owned by F2G. Shionogi & is the other company associated in development or marketing of Olorofim.
Olorofim (F-901318) is under development for the treatment of invasive fungal infections, such as invasive aspergillosis (including azole-resistant strains), scedosporiosis, lomentosporiosis, fusariosis, scopulariopsosis, and coccidioidomycosis. The drug candidate is formulated as tablet and administered through oral route and also administered through intravenous route. The drug candidate belongs to the orotomide class which acts by targeting dihydroorotate dehydrogenase (DHODH). The drug candidate is developed based on MycoBank technology. It was also under development for the treatment of aspergillosis as the intravenous formulation.
Shionogi & Overview
Shionogi & (Shionogi) focuses on the research, development, manufacturing, and marketing of pharmaceutical products, diagnostic reagents, and medical devices. It develops innovative products and services in collaboration with its partners. The company offers prescription drugs, over-the-counter (OTC) drugs, and diagnostic products for the therapeutic areas including metabolic disorders, infectious diseases, pain/central nervous system (CNS), and cancer. It offers contract development and manufacturing facilities including all stages from drug development to commercial manufacturing. The company operates a network of subsidiaries, branches, sales offices manufacturing plants, and research laboratories across Japan, China, Taiwan; North America and Europe. Shionogi is headquartered in Osaka, Japan.
The company reported revenues of (Yen) JPY335,138 million for the fiscal year ended March 2022 (FY2022), an increase of 12.8% over FY2021. In FY2022, the company’s operating margin was 32.9%, compared to an operating margin of 39.5% in FY2021. In FY2022, the company recorded a net margin of 34.1%, compared to a net margin of 37.6% in FY2021. The company reported revenues of JPY78,939 million for the second quarter ended September 2022, an increase of 9.9% over the previous quarter.
Quick View – Olorofim
|Highest Development Stage|